Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy - Wikidata - awgldk - TriplyDB

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

http://www.wikidata.org/entity/Q28080752

about

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.

P2860

Q36438920-C7A82DAD-6A4D-408D-9088-27C8D8AC30F2 Q36445132-ACCF8645-B60B-4B3A-A0B0-0DE655292592 Q37067118-18C09083-CBD9-4603-8303-9D1E20D317F6 Q37287684-D269353C-87BC-4CAB-9621-008972E3405B Q37578288-900BFBB7-8D2A-43BA-9F5D-E599FE546859 Q38393581-D9BB6915-ACD0-444E-B766-D355F04785C2 Q38821075-45C3DB85-4E3C-4AC8-B4B0-E686A368CA73 Q38927209-2B016CFD-C0CB-431D-A373-08A7D236D526 Q39147495-E2EA710D-C776-4F96-9B47-C59F7C5161FB Q39150134-669E7314-F3E2-471F-AEC2-7FB4B093D589 Q39160612-3FD0AB04-91A7-4F16-ABB7-9B611D5D9E06 Q39357557-666D2040-BD26-46FF-B6B0-68324B212943 Q39900651-410E06B2-CA76-466A-B8D6-9DCBFF2DB6EB Q40597366-7FD27169-C930-4EA4-9A29-EA565730D970 Q40697687-102D1B89-6ADF-456F-AF87-4BAA94BF9F83 Q55093102-84953D91-19C8-49D7-9ED7-233E728D9FC7

P2860

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

http://www.wikidata.org/entity/Q28080752

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@ast

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@en

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@nl

type

label

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@ast

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@en

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@nl

prefLabel

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@ast

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@en

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@nl

P1433

Q28080752-BB77FE68-8361-4CE2-BD38-FCFBC42A81B3

P1476

Q28080752-72E39D12-95A3-4B96-8438-94B0A83FDBE3

P2093

Q28080752-480C40F1-E7A2-41E5-A295-1A2507B27052

Q28080752-5A5BE470-6202-4217-BDB6-0B3E7CAA299C

Q28080752-8DCBA3E3-4031-40A9-8543-0A667E990466

Q28080752-A8489FF3-D3B6-461A-A277-33C39BF92CFA

Q28080752-C389DE00-7743-469B-8D37-ED9C43A96F90

Q28080752-E29019E4-5133-4D2A-ACEB-05B8EE88B18F

P275

Q28080752-D4B99738-B499-4661-B26B-4E347C02C43B

P2860

Q28080752-04910417-4272-4DB1-9428-C6FC92157546

Q28080752-05F5D06D-3B98-49CE-9434-0B706BE0E6EF

Q28080752-0B7AE175-6B18-4F12-AEC6-607CF57CD197

Q28080752-0B86604E-374A-4A39-BCA1-3862BA2A88DF

Q28080752-0DE1F39D-13E1-45F1-AF4D-1295D0628FE9

Q28080752-1A7DBBA8-CE95-449C-8ED8-239E8F624D3F

Q28080752-1D66A916-65C7-40E6-B357-9573BD3F4DD8

Q28080752-1F5B5177-3CF2-4955-8209-D2129374A155

Q28080752-223667B8-B4D4-4E9E-8BE4-211ADFFBF46B

Q28080752-247B1DDE-E998-4E76-A23D-2CF50F3EFBED

P2888

Q28080752-696A1893-B70E-45D3-AD3C-5F5461C40B1C

P304

Q28080752-3628508F-4130-4915-8A56-DBD8D7586FA6

P31

Q28080752-3F073001-C0F3-46B6-8A84-FA40811AC594

Q28080752-CCAC4870-423B-4038-8A2F-872E3BB223C9

P356

Q28080752-2F349D7F-8D52-4FC0-A5A7-86C2590A4A24

P407

Q28080752-0276B703-9DC6-4A89-9CD4-60EC422D3F30

P433

Q28080752-405EA0DE-2E5B-4C6E-B36D-208806C732B2

P478

Q28080752-E4D1BA19-9DF5-4DB9-BAA7-1CEE7CCCC73A

P5008

Q28080752-A0A49730-8687-433B-AFAC-AE224953E364

P577

Q28080752-080FF2E5-05F3-4F44-A77D-F43DA3C1A9D0

Q28080752-722862A3-8CF1-4F40-A968-2D9BB12F74F6

P5875

Q28080752-058E9AAD-1F20-4933-8ABC-707F3A870D98

P6179

Q28080752-0DEE5784-502B-4885-9A77-D7B1E1304BDF

P698

Q28080752-A8308D2B-3C00-4E5E-8D78-13DBC683A4C7

P921

Q28080752-09AF4126-15C8-4CD6-9E4F-1D809A260F37

Q28080752-230B33CC-9338-4F2F-8081-974AB0086F9F

Q28080752-529AA799-4372-408F-91A7-3FF58C1E7851

Q28080752-65BC366B-2476-43D4-B0EF-A3B980FD8668

Q28080752-8170276B-B4EF-4478-8F4B-2E9B4733141A

Q28080752-85F6C043-60C2-4798-B74C-B3F21A5A5EE4

Q28080752-CD960D0B-856C-4FFF-ABA6-8113F54A0328

P932

Q28080752-EC0F781C-19EA-462A-A395-39DFE72C605B

P356

S40262-015-0317-8

P1433

Clinical Pharmacokinetics

P1476

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

@en

P2093

Akshanth R. Polepally

http://www.w3.org/2001/XMLSchema#string

Barbara H. McGovern

http://www.w3.org/2001/XMLSchema#string

Jennifer R. King

http://www.w3.org/2001/XMLSchema#string

Prajakta S. Badri

http://www.w3.org/2001/XMLSchema#string

Rajeev M. Menon

http://www.w3.org/2001/XMLSchema#string

Sandeep Dutta

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides

Boceprevir for previously treated chronic HCV genotype 1 infection

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes

Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam

CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes

Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes

Telaprevir for retreatment of HCV infection

Sofosbuvir for previously untreated chronic hepatitis C infection

Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

P2888

s40262-015-0317-8

P304

275-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-015-0317-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281451025

http://www.w3.org/2001/XMLSchema#string

P6179

1038693879

http://www.w3.org/2001/XMLSchema#string

P698

26330025

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

heterocyclic compound

polycyclic compound

P932

4761011

http://www.w3.org/2001/XMLSchema#string